Shanghai-based radiotherapeutics startup, Full-Life Technologies, has completed a $37 million Series A financing round, led by Beijing Chinese venture capital firm Sequoia China.
Full-Life said it will use the funds to advance its lead radiopharmaceutical compounds into first-in-human studies next year and accelerate the development of global radioisotope production and logistics capabilities.
Full-Life's discovery platform includes optimized single domain antibodies, peptides and linkers to radionuclides. According to the company, the platform is designed to attack the two core issues that exist in radiopharmaceuticals: 1) the ability to produce radioisotope in high quality and quantity and 2) the creation of an innovative translational and biology research platform targeting the radio-pharma treatments of tomorrow.
Sequoia China focuses its funding on technology, consumer and health care sectors. According to Sequoia, the firm has backed more than 900 companies in China.
"Radiopharmaceuticals represent an enormous, largely untapped opportunity for developing precision oncology drugs," said Sequoia China managing director Trency Gu. "Full-Life is building a powerful end-to-end solution to discover and develop innovative next-generation radiopharmaceuticals for cancer patients. The company has built an outstanding team to execute on that vision and has rapidly established a robust pipeline."
Yunion Healthcare Ventures, Junson Capital, CD Capital and Kunlun Capital also joined the Series A financing round.